Dashboard
Weak Long Term Fundamental Strength with an average Return on Equity (ROE) of 3.73%
- Poor long term growth as Net Sales has grown by an annual rate of 1.97% and Operating profit at 1.01% over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of 1.92
Flat results in Sep 26
Stock is technically in a Bearish range
Consistent Underperformance against the benchmark over the last 3 years
Stock DNA
Pharmaceuticals & Biotechnology
INR 35 Cr (Micro Cap)
22.00
19
2.72%
-0.05
3.71%
0.85
Total Returns (Price + Dividend) 
Latest dividend: 1.000523560209424 per share ex-dividend date: Sep-04-2026
Risk Adjusted Returns v/s 
Returns Beta
News

Sandu Pharmaceuticals Downgraded to Strong Sell Amid Flat Financials and Weak Fundamentals
Sandu Pharmaceuticals Ltd has been downgraded from a Sell to a Strong Sell rating by MarketsMOJO as of 16 Nov 2026, reflecting deteriorating fundamentals and subdued financial performance. Despite an attractive valuation, the company’s weak quality metrics, stagnant financial trends, and poor technical indicators have prompted a reassessment of its investment appeal.
Read More
Sandu Pharmaceuticals Downgraded to Strong Sell Amid Weak Fundamentals and Bearish Technicals
Sandu Pharmaceuticals Ltd has been downgraded from a Sell to a Strong Sell rating by MarketsMOJO as of 19 Oct 2026, reflecting deteriorating technical indicators and persistently weak financial fundamentals. The micro-cap pharmaceutical company’s stock performance continues to lag behind benchmarks, prompting a reassessment across quality, valuation, financial trend, and technical parameters.
Read More
Sandu Pharmaceuticals Ltd Rating Upgraded to Sell Amid Technical Improvements
Sandu Pharmaceuticals Ltd has seen its investment rating upgraded from Strong Sell to Sell, driven primarily by a shift in technical indicators despite persistent fundamental weaknesses. The micro-cap pharmaceutical company’s recent flat financial performance and long-term underperformance contrast with modest improvements in technical trends, prompting a nuanced reassessment of its outlook.
Read More Announcements 
Announcement under Regulation 30 (LODR)-Newspaper Publication
16-Nov-2026 | Source : BSENewspaper publication in respect of Unaudited Financials for the Q and Half Year ended 30th September 2026
Board Meeting Outcome for Outcome Of The Board Meeting Dated 14Th November 2026
14-Nov-2026 | Source : BSEOutcome of the Board Meeting dated 14th November 2026
Statement Of Deviation And Variation Of Funds For Q Ended 30Th September 2026
14-Nov-2026 | Source : BSEstatement of deviation and variation of funds for q ended 30th sept 2026
Corporate Actions 
No Upcoming Board Meetings
Sandu Pharmaceuticals Ltd has declared 10% dividend, ex-date: 04 Sep 26
No Splits history available
No Bonus history available
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Sep 2026
Shareholding Compare (%holding) 
Non Institution
None
Held by 0 Schemes
Held by 0 FIIs
Umesh Bhaskar Sandu (14.37%)
Sanmark Realty And Finance Private Limited (5.63%)
37.08%
Quarterly Results Snapshot (Standalone) - Sep'26 - QoQ
QoQ Growth in quarter ended Sep 2026 is 18.55% vs -2.73% in Jun 2026
QoQ Growth in quarter ended Sep 2026 is 243.48% vs 475.00% in Jun 2026
Half Yearly Results Snapshot (Standalone) - Sep'25
Growth in half year ended Sep 2025 is -1.24% vs 1.43% in Sep 2024
Growth in half year ended Sep 2025 is 11.94% vs 1.52% in Sep 2024
Nine Monthly Results Snapshot (Standalone) - Dec'25
YoY Growth in nine months ended Dec 2025 is -0.08% vs 2.77% in Dec 2024
YoY Growth in nine months ended Dec 2025 is 40.65% vs 41.38% in Dec 2024
Annual Results Snapshot (Standalone) - Mar'26
YoY Growth in year ended Mar 2026 is 4.08% vs -0.13% in Mar 2025
YoY Growth in year ended Mar 2026 is 14.19% vs 6.16% in Mar 2025